ARV-471, also known as vepdegestrant, is a pioneering proteolysis-targeting chimera (PROTAC) designed as an oral estrogen receptor degrader. This therapeutic agent is indicated for the treatment of patients… Read more
ARV-471, also known as vepdegestrant, is a pioneering proteolysis-targeting chimera (PROTAC) designed as an oral estrogen receptor degrader. This therapeutic agent is indicated for the treatment of patients with estrogen receptor-positive, HER2-negative, and ESR1-mutated advanced or metastatic breast cancer, functioning by inducing the targeted degradation of the estrogen receptor protein. To support the clinical and research development of this compound, laboratories utilize a range of related reference standards. These include stable isotope labelled compounds, such as deuterated variants, which serve as essential internal standards for the accurate quantification of the drug in biological matrices. Furthermore, high-quality reference materials are indispensable for rigorous impurity profiling and method validation during quality control processes, ensuring that analytical measurements remain precise and reliable throughout the lifecycle of pharmaceutical development and manufacturing.